


**AMENDMENTS TO THE CLAIMS**

Please amend claims 2, 3 and 17. The following listing of claims will replace all prior versions, and listings, of the claims in the application.

1. (Cancelled)

2. (Currently amended) A method for preventing or treating overactive bladder in a patient comprising administering to a patient in need thereof an effective amount of a Vitamin D<sub>3</sub> compound thereby preventing or treating overactive bladder in said patient; wherein the Vitamin D<sub>3</sub> compound is not a compound of formula



wherein:

X<sub>1</sub> is H<sub>2</sub> or CH<sub>2</sub>;


A<sub>2</sub> is a single, a double or a triple bond;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are each independently C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxyalkyl, or fluoroalkyl;

Z is -OH, -NH<sub>2</sub> or -SH;

the configuration at C<sub>20</sub> is R or S; or pharmaceutically acceptable esters[,] and salts[,] and prodrugs thereof; and

wherein the Vitamin D<sub>3</sub> compound is not a compound of formula



wherein:

X<sub>1</sub> and X<sub>2</sub> are each independently H<sub>2</sub> or CH<sub>2</sub>, provided X<sub>1</sub> and X<sub>2</sub> are not both =CH<sub>2</sub>;

R<sub>1</sub> and R<sub>2</sub> are each independently hydroxyl, OC(O)C<sub>1</sub>-C<sub>4</sub> alkyl, OC(O)hydroxyalkyl or OC(O)haloalkyl, provided that R<sub>1</sub> and R<sub>2</sub> are not both hydroxyl;

R<sub>3</sub> and R<sub>4</sub> are each independently hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxyalkyl or haloalkyl or R<sub>3</sub> and R<sub>4</sub> taken together with C<sub>20</sub> form C<sub>3</sub>-C<sub>6</sub> cycloalkyl; and

R<sub>5</sub> and R<sub>6</sub> are each independently C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxyalkyl or haloalkyl; or pharmaceutically acceptable esters[,] and salts[,] and prodrugs thereof.

3. (Currently amended) The method according to claim 2, which further comprises the step of obtaining or synthesizing the Vitamin D<sub>3</sub> compound.

4. (Previously presented) The method according to claim 3, wherein the Vitamin D<sub>3</sub> compound is formulated in a pharmaceutical composition together with a pharmaceutically acceptable diluent or carrier.

5. (Cancelled)

6. (Cancelled)

7. (Withdrawn) A kit containing a Vitamin D compound together with instructions directing administration of the Vitamin D compound to a patient in need of prevention or treatment of bladder dysfunction thereby to prevent or treat bladder dysfunction in said patient.

8. (Withdrawn) A kit according to claim 7 wherein the Vitamin D compound is formulated in a pharmaceutical composition together with a pharmaceutically acceptable diluent or carrier.

9. (Previously presented) The method according to claim 2, wherein said Vitamin D<sub>3</sub> compound is a Vitamin D receptor agonist.

10 - 12. (Cancelled)


13. (Previously presented) The method according to claim 2, wherein said patient is a male.

14. (Cancelled)

15. (Previously presented) The method according to claim 2, wherein said patient is a female.

16. (Previously Presented) The method according to claim 2, wherein the patient is a human.

17. (Currently Amended) ~~The A method according to claim 2, wherein said Vitamin D<sub>3</sub> compound is for preventing or treating overactive bladder in a patient comprising administering to a patient in need thereof an effective amount of a compound of the formula~~



wherein:

X is H<sub>2</sub> or CH<sub>2</sub>;

R<sub>1</sub> is hydrogen, hydroxy or fluorine;

R<sub>2</sub> is hydrogen or methyl;

R<sub>3</sub> is hydrogen or methyl, wherein when R<sub>2</sub> or R<sub>3</sub> is methyl, R<sub>3</sub> or R<sub>2</sub> must be hydrogen;

R<sub>4</sub> is methyl, ethyl or trifluoromethyl;


R<sub>5</sub> is methyl, ethyl or trifluoromethyl;

A is a single or double bond; and

B is a single, E-double, Z-double or triple bond; or pharmaceutically acceptable esters and salts thereof.


18. (Previously Presented) The method according to claim 17, wherein each of R<sub>4</sub> and R<sub>5</sub> is methyl or ethyl.

19. (Previously presented) The method according to claim 18, wherein said Vitamin D<sub>3</sub> compound is 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol, having the formula:




20. (Previously presented) The method according to claim 2, wherein said Vitamin D<sub>3</sub> compound is 1,25-dihydroxy-16-ene-23-yne cholecalciferol.

21. (Previously presented) The method according to claim 2, wherein said Vitamin D<sub>3</sub> compound is 1,3-di-O-acetyl-1,25-dihydroxy-16,23Z-diene-26,27-hexafluoro-19-norcholecalciferol, having the formula:



22. (Previously presented) The method according to claim 2, wherein said Vitamin D<sub>3</sub> compound is calcitriol.

23. (Previously presented) The method according to claim 2, wherein said Vitamin D<sub>3</sub> compound is a compound of the formula



wherein:

X<sub>1</sub> and X<sub>2</sub> are H<sub>2</sub> or CH<sub>2</sub>, wherein X<sub>1</sub> and X<sub>2</sub> are not CH<sub>2</sub> at the same time;

A is a single or double bond;

A<sub>2</sub> is a single, double or triple bond;

A<sub>3</sub> is a single or double bond;

R<sub>1</sub> and R<sub>2</sub> are hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl or 4-hydroxy-4-methylpentyl, wherein R<sub>1</sub> and R<sub>2</sub> are not both hydrogen;


R<sub>5</sub> is hydrogen, H<sub>2</sub> or oxygen;

R<sub>3</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxyalkyl or haloalkyl; and

R<sub>4</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxyalkyl or haloalkyl.

24. (Previously presented) The method according to claim 23, wherein the compound is 1,25-dihydroxy-16-ene-23-yne cholecalciferol.

25. (Previously presented) The method according to claim 2, wherein said Vitamin D<sub>3</sub> compound is a compound of the formula



$A_1$  is single or double bond;

$A_2$  is a single, double or triple bond;

$X_1$  and  $X_2$  are each independently  $\text{H}_2$  or  $\text{CH}_2$ , provided  $X_1$  and  $X_2$  are not both  $\text{CH}_2$ ;


$R_1$  and  $R_2$  are each independently  $\text{OC(O)C}_1\text{-C}_4$  alkyl,  $\text{OC(O)hydroxyalkyl}$  or  
 $\text{OC(O)haloalkyl}$ ;

$R_3$ ,  $R_4$  and  $R_5$  are each independently hydrogen,  $\text{C}_1\text{-C}_4$  alkyl, hydroxyalkyl, or  
haloalkyl, or  $R_3$  and  $R_4$  taken together with  $\text{C}_{20}$  form  $\text{C}_3\text{-C}_6$  cycloalkyl;


$R_6$  and  $R_7$  are each independently  $\text{C}_1\text{-C}_4$  alkyl or haloalkyl; and

$R_8$  is  $\text{H}$ ,  $-\text{COC}_1\text{-C}_4$  alkyl,  $-\text{COhydroxyalkyl}$  or  $-\text{COhaloalkyl}$ .

26. (Previously presented) The method according to claim 25, wherein the compound is 1,3-di-O-acetyl-1,25-dihydroxy-16,23Z-diene-26,27-hexafluoro-19-norcholecalciferol:



27. (Previously presented) The method according to claim 2, wherein said Vitamin D<sub>3</sub> compound is a compound of the formula:



X<sub>1</sub> is H<sub>2</sub> or CH<sub>2</sub>;


A<sub>2</sub> is a single, a double or a triple bond;

R<sub>f</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxyalkyl, or haloalkyl;

R<sub>4</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxyalkyl or haloalkyl; and

the configuration at C<sub>20</sub> is R or S.

28. (Previously presented) The method according to claim 27, wherein said vitamin D compound is 1,25-dihydroxy-21-(3-hydroxy-3-methylbutyl)-19-nor-cholecalciferol:



29. (Previously presented) The method according to claim 2, wherein said Vitamin D<sub>3</sub> compound is a compound of the formula:

1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol;

1,25-Dihydroxy-21-(2R,3-dihydroxy-3-methyl-butyl)-20R-cholecalciferol;

1,3-Di-O-acetyl-1,25-dihydroxy-16-ene-cholecalciferol;

1,3-Di-O-acetyl-1,25-dihydroxy-20-cyclopropyl-cholecalciferol;

1,3-Di-O-acetyl-1,25-dihydroxy-23-yne-cholecalciferol;

1,3-Di-O-acetyl-1,25-dihydroxy-16-ene-23-yne-cholecalciferol;

1,25-Dihydroxy-16,23Z-diene-20-cyclopropyl-26,27-hexafluoro-cholecalciferol;

1,3-Di-O-acetyl-1,25-dihydroxy-16,23Z-diene-26,27-hexafluoro-19-norcholecalciferol;

1,25-Dihydroxy-16,23E-diene-20-cyclopropyl-26,27-hexafluoro-cholecalciferol;

1,3,25-Tri-O-acetyl-1,25-dihydroxy-20-cyclopropyl-23-yne-26,27-hexafluoro-19-norcholecalciferol;

1,3-Di-O-acetyl -1,25-dihydroxy-20-cyclopropyl-23-yne-26,27-hexafluoro-19-norcholecalciferol;

1,25-dihydroxy-21(3-hydroxy-3-trifluoromethyl-4-trifluoro-butynyl)-26,27-hexadeutero-19-nor-20S-cholecalciferol;  
1,3-Di-O-acetyl-1,25-dihydroxy-16,23E-diene-cholecalciferol;  
1,25-dihydroxy-16-ene-20-cyclopropyl-cholecalciferol;  
1,3-Di-O-acetyl-1,25-dihydroxy-20-cyclopropyl-23-yne-cholecalciferol;  
1,3-Di-O-acetyl-1,25-dihydroxy-16-ene-24-keto-19-nor-cholecalciferol;  
1,3-Di-O-acetyl-1,25-dihydroxy-20-cyclopropyl-23Z-ene-26,27-hexafluoro-19-nor-cholecalciferol;  
1,3-Di-O-acetyl-1,25-dihydroxy-16-ene-23-yne-26,27-hexafluoro-cholecalciferol;  
1,25-Dihydroxy-16-ene-20-cyclopropyl-23-yne-26,27-hexafluoro-cholecalciferol;  
1,3-Di-O-acetyl-1,25-dihydroxy-16-ene-19-nor-cholecalciferol;  
1,25-dihydroxy-21-(3-hydroxy-3-methylbutyl)-19-nor-cholecalciferol;  
1,25-dihydroxy-21-(3-hydroxy-3-methylbutyl)-19-nor-cholecalciferol;  
1,3-Di-O-acetyl-1,25-dihydroxy-16-ene-23-yne-19-nor-cholecalciferol; or  
1,3-Di-O-acetyl-1,25-dihydroxy-20-cyclopropyl-23E-ene-26,27-hexafluoro-19-nor-cholecalciferol.

30. (Previously presented) The method according to claim 2, wherein said

Vitamin D<sub>3</sub> compound is a compound of the formula:

1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol;  
1,3-Di-O-acetyl-1,25-dihydroxy-16-ene-cholecalciferol;  
1,3-Di-O-acetyl-1,25-dihydroxy-16-ene-23-yne-cholecalciferol;  
1,25-Dihydroxy-16,23E-diene-20-cyclopropyl-26,27-hexafluoro-cholecalciferol;  
1,3-Di-O-acetyl -1,25-dihydroxy-20-cyclopropyl-23-yne-26,27-hexafluoro-19-nor-cholecalciferol;

1,3-Di-O-acetyl-1,25-dihydroxy-16,23E-diene-cholecalciferol;

1,3-Di-O-acetyl-1,25-dihydroxy-16-ene-23-yne-26,27-hexafluoro-cholecalciferol;

1,3-Di-O-acetyl-1,25-dihydroxy-16-ene-19-nor-cholecalciferol; or

1, 3-Di-O-acetyl-1,25-dihydroxy-20-cyclopropyl-23E-ene-26,27-hexafluoro-19-nor-cholecalciferol.

31. (Previously presented) The method according to claim 2, wherein said Vitamin D<sub>3</sub> compound is calcitriol.